Novel Coronavirus (SARS-CoV-2/COVID-19)
Some health care needs are predictable but some are not. We can plan around giving birth, having a heart bypass, or scheduling a colonoscopy. But there are also surprises, such as injuries from accidents, or a cancer that appears with no family history … or COVID-19.
We’ve been discussing for months how hospitals and health systems are contending with the worst financial crisis in their history as they continue to serve on the front lines of the fight against COVID-19.
In anticipation of the likely issuance of emergency use authorizations (EUAs) for at least two monoclonal antibody therapeutic drugs developed to treat certain COVID-19 positive patients, providers should begin planning for the distribution and administration process of these therapeutics.
The Centers for Medicare & Medicaid Services issued a final rule updating the home health prospective payment system for calendar year 2021.
The Federal Reserve Board reduced the minimum loan size for three Main Street Lending Program facilities from $250,000 to $100,000 and adjusted associated fees to support smaller organizations facing continued revenue shortfalls due to the pandemic.
This Special Bulletin details the Office of the National Coordinator (ONC) for Health Information Technology’s interim final rule with comment period to delay the Nov. 2 compliance date for the information blocking provisions of ONC’s Cures Act final rule, while also extending timelines for certain…
“The COVID-19 pandemic has proved that crisis tends to be a driver of innovation,” writes Jonathan Bandel, vice president of strategy and innovation for New York’s White Plains Hospital.
The Food and Drug Administration updated its guidance on enforcement policy for non-invasive remote monitoring devices that support patient monitoring during the COVID-19 public health emergency.
Over 10,000 eligible nursing homes, or 76% of the field, will receive a portion of $333 million in COVID-19 Provider Relief Funds for meeting infection control and mortality criteria in effect from August through September.
The departments of Health and Human Services and Defense have agreed to purchase the first 300,000 doses of the investigational antibody drug bamlanivimab, also known as LY-CoV555, which state and territorial health departments will distribute to health care facilities for use in COVID-19…